Log in

NASDAQ:SAVACassava Sciences Stock Price, Forecast & News

+0.17 (+5.30 %)
(As of 08/14/2020 04:00 PM ET)
Today's Range
Now: $3.38
50-Day Range
MA: $3.21
52-Week Range
Now: $3.38
Volume2.18 million shs
Average Volume3.20 million shs
Market Capitalization$83.76 million
P/E RatioN/A
Dividend YieldN/A
Cassava Sciences, Inc., a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.08 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SAVA



Sales & Book Value

Annual SalesN/A
Book Value$1.01 per share


Net Income$-4,630,000.00


Market Cap$83.76 million
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
+0.17 (+5.30 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SAVA News and Ratings via Email

Sign-up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Cassava Sciences (NASDAQ:SAVA) Frequently Asked Questions

How has Cassava Sciences' stock price been impacted by COVID-19?

Cassava Sciences' stock was trading at $4.24 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SAVA stock has decreased by 20.3% and is now trading at $3.38.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Cassava Sciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Cassava Sciences

When is Cassava Sciences' next earnings date?

Cassava Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Cassava Sciences

How were Cassava Sciences' earnings last quarter?

Cassava Sciences Inc (NASDAQ:SAVA) released its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01.
View Cassava Sciences' earnings history

When did Cassava Sciences' stock split? How did Cassava Sciences' stock split work?

Shares of Cassava Sciences reverse split on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 9th 2017. An investor that had 100 shares of Cassava Sciences stock prior to the reverse split would have 14 shares after the split.

What price target have analysts set for SAVA?

2 brokers have issued 12-month target prices for Cassava Sciences' stock. Their forecasts range from $12.00 to $16.00. On average, they anticipate Cassava Sciences' share price to reach $14.00 in the next twelve months. This suggests a possible upside of 314.2% from the stock's current price.
View analysts' price targets for Cassava Sciences

Has Cassava Sciences been receiving favorable news coverage?

Media stories about SAVA stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cassava Sciences earned a news impact score of 0.6 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about Cassava Sciences

Are investors shorting Cassava Sciences?

Cassava Sciences saw a increase in short interest during the month of May. As of May 29th, there was short interest totaling 2,970,000 shares, an increase of 19.8% from the May 14th total of 2,480,000 shares. Based on an average daily trading volume, of 3,600,000 shares, the days-to-cover ratio is currently 0.8 days.
View Cassava Sciences' Short Interest

Who are some of Cassava Sciences' key competitors?

What other stocks do shareholders of Cassava Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), DURECT (DRRX), NVIDIA (NVDA), Advanced Micro Devices (AMD), Opko Health (OPK), Exelixis (EXEL), Immunomedics (IMMU), Novavax (NVAX), Synergy Pharmaceuticals (SGYP) and Sorrento Therapeutics (SRNE).

Who are Cassava Sciences' key executives?

Cassava Sciences' management team includes the following people:
  • Mr. Remi Barbier, Founder, Chairman, CEO & Pres (Age 59)
  • Mr. Eric J. Schoen, Chief Financial Officer (Age 51)
  • Dr. Nadav Friedmann, COO, Chief Medical Officer & Director (Age 76)
  • Dr. Michael Marsman Pharm.D., Sr. VP of Regulatory Affairs

What is Cassava Sciences' stock symbol?

Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."

Who are Cassava Sciences' major shareholders?

Cassava Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (0.55%), Jefferies Group LLC (0.40%), New York State Common Retirement Fund (0.13%), Bank of Montreal Can (0.13%), WINTON GROUP Ltd (0.13%) and Creative Planning (0.09%). Company insiders that own Cassava Sciences stock include Armistice Capital Master Fund, Armistice Capital, Llc, Eric Schoen, Remi Barbier and Sanford Robertson.
View institutional ownership trends for Cassava Sciences

Which major investors are selling Cassava Sciences stock?

SAVA stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and Bank of Montreal Can.
View insider buying and selling activity for Cassava Sciences

Which major investors are buying Cassava Sciences stock?

SAVA stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, New York State Common Retirement Fund, WINTON GROUP Ltd, Jefferies Group LLC, American International Group Inc., State Board of Administration of Florida Retirement System, Creative Planning, and Bank of America Corp DE. Company insiders that have bought Cassava Sciences stock in the last two years include Eric Schoen, Remi Barbier, and Sanford Robertson.
View insider buying and selling activity for Cassava Sciences

How do I buy shares of Cassava Sciences?

Shares of SAVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cassava Sciences' stock price today?

One share of SAVA stock can currently be purchased for approximately $3.38.

How big of a company is Cassava Sciences?

Cassava Sciences has a market capitalization of $83.76 million. The company earns $-4,630,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Cassava Sciences employs 9 workers across the globe.

What is Cassava Sciences' official website?

The official website for Cassava Sciences is www.cassavasciences.com.

How can I contact Cassava Sciences?

Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The company can be reached via phone at 512-501-2444 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.